Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade

Activation of systemic immune responses using PD-1 checkpoint inhibitors is an essential approach to cancer therapy. Yet, the extent of benefit relative to risk of immune related adverse events (irAE) varies widely among patients. Here, we study endocrine irAE from 7 clinical trials across 6 cancers...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Zia, Hammer, Christian, Carroll, Jonathan, Di Nucci, Flavia, Acosta, Sergio Ley, Maiya, Vidya, Bhangale, Tushar, Hunkapiller, Julie, Mellman, Ira, Albert, Matthew L., McCarthy, Mark I., Chandler, G. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184890/
https://www.ncbi.nlm.nih.gov/pubmed/34099659
http://dx.doi.org/10.1038/s41467-021-23661-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184890/
https://www.ncbi.nlm.nih.gov/pubmed/34099659
http://dx.doi.org/10.1038/s41467-021-23661-4

Ejemplares similares